VolitionRx Past Earnings Performance

Past criteria checks 0/6

VolitionRx's earnings have been declining at an average annual rate of -15.3%, while the Medical Equipment industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 68.7% per year.

Key information

-15.3%

Earnings growth rate

-1.8%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate68.7%
Return on equityn/a
Net Margin-2,323.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How VolitionRx makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSEAM:VNRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-301516
30 Jun 241-321618
31 Mar 241-351719
31 Dec 231-351720
30 Sep 231-341719
30 Jun 231-331619
31 Mar 230-311717
31 Dec 220-301715
30 Sep 220-311815
30 Jun 220-302012
31 Mar 220-281713
31 Dec 210-271513
30 Sep 210-241214
30 Jun 210-21815
31 Mar 210-21715
31 Dec 200-20715
30 Sep 200-19613
30 Jun 200-19613
31 Mar 200-18612
31 Dec 190-16610
30 Sep 190-17611
30 Jun 190-17611
31 Mar 190-18611
31 Dec 180-18711
30 Sep 180-18710
30 Jun 180-17710
31 Mar 180-1679
31 Dec 170-1578
30 Sep 170-1468
30 Jun 170-1368
31 Mar 170-1358
31 Dec 160-1258
30 Sep 160-1257
30 Jun 160-1147
31 Mar 160-1046
31 Dec 150-1046
30 Sep 150-836
30 Jun 150-1135
31 Mar 150-834
31 Dec 140-824
30 Sep 140-823
30 Jun 140-323

Quality Earnings: VNRX is currently unprofitable.

Growing Profit Margin: VNRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VNRX is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare VNRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VNRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15%).


Return on Equity

High ROE: VNRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 23:44
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

VolitionRx Limited is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jan WaldBenchmark Company
Bruce JacksonBenchmark Company